Bold Leadership Change to Overcome Regulatory Setbacks

Sarepta Therapeutics (SRPT) has appointed Michael Severino, former Executive Vice President at AbbVie and CEO of Tessera Therapeutics, as its new Chief Executive Officer, effective July 28, 2026. Doug Ingram, who has led the company since 2017, will retire due to family health issues and serve as an advisor until the end of 2026. This leadership change is a strategic move by the Board of Directors to overcome recent regulatory hurdles and commercial challenges and to improve the company's overall performance. With Severino's arrival, Sarepta aims to solidify its position as a leader in gene therapy and restore market confidence.

Challenges in Establishing Elevidys in the Market and Overcoming Regulatory Obstacles

Elevidys, Sarepta's key asset and the world's first single-dose gene therapy for Duchenne Muscular Dystrophy (DMD), is an ultra-high-priced drug with a cost of approximately $3.2 million USD. While it received Traditional Approval from the FDA in June 2024, it faced a major setback in June 2025 when the FDA decided to revise the label, removing the indication for non-ambulatory patients and adding a Boxed Warning for severe liver damage. This has limited patient access, and as a result, sales, which were $820.8 million in 2024, slowed to $898.7 million in 2025, with quarterly sales declining. The new CEO must defend sales growth within the narrowed prescribing guidelines and work to resume prescribing for non-ambulatory patients through new immunosuppressive therapies.

Competition from Latecomers and Strategies to Maintain Market Dominance

In terms of competitive landscape, Sarepta has secured a dominant market position after Pfizer's (PFE) DMD gene therapy candidate, fordadistrogene movaparvovec, was completely halted in June 2024 following a Phase 3 trial failure. However, Regenxbio (RGNX) and Solid Biosciences (SLDB) are rapidly progressing their RGX-202 and SGT-003 candidates, respectively, through Phase 1/2 trials. Severino is considered a suitable candidate to fend off these latecomers, as he has extensive experience in large-scale clinical R&D and multiple commercialization successes at AbbVie. In particular, with the confirmation of safety and efficacy in the 3-year long-term data from the Phase 3 (EMBARK) trial released in early 2026, the company is expected to accelerate its global market expansion.

Prospects for Diversifying the Pipeline Based on Next-Generation Platforms

Tessera Therapeutics, which Severino previously led, is a biotech company with innovative gene writing technology. His deep expertise in genetic medicine will contribute to expanding Sarepta's technological horizons. Sarepta faces the immediate challenge of diversifying beyond its existing Adeno-Associated Virus (AAV) platform and discovering new modalities to reduce its reliance on a single product. The industry expects that Severino's scientific insight and network will lead to active in-licensing or strategic partnerships, strengthening the pipeline. As a result, this CEO change is a bold move to achieve two key goals: defending Elevidys sales in the short term and securing new growth drivers in the medium to long term.